Do analysts recommend NXTS or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexentis Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PRPH or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRPH or VCNX more profitable?

Vaccinex has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vaccinex's return on equity of 0.00% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets ProPhase Labs -825.01% -482.05% -88.90% Vaccinex N/A N/A -383.58%

Do analysts rate GRI or PRPH?

GRI Bio presently has a consensus price target of $32.00, suggesting a potential upside of 1,782.35%. Given GRI Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe GRI Bio is more favorable than ProPhase Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRI or PRPH more profitable?

GRI Bio has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. GRI Bio's return on equity of -199.52% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% ProPhase Labs -825.01% -482.05% -88.90%

Do analysts rate PRPH or MBRX?

Moleculin Biotech has a consensus target price of $22.00, suggesting a potential upside of 5,011.52%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than ProPhase Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

ProPhase Labs (PRPH) Competitors

$0.05 +0.01 (+42.29%)

As of 08/10/2026 01:58 PM Eastern

Compare

PRPH vs. NXTS, VCNX, GRI, CASI, and MBRX

Should you buy ProPhase Labs stock or one of its competitors? ProPhase Labs's main competitors and comparable companies include Nexentis Technologies (NXTS), Vaccinex (VCNX), GRI Bio (GRI), CASI Pharmaceuticals (CASI), and Moleculin Biotech (MBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ProPhase Labs compare to Nexentis Technologies?

Nexentis Technologies (NASDAQ:NXTS) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Nexentis Technologies has a beta of 1.83, suggesting that its stock price is 83% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexentis Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nexentis Technologies has higher earnings, but lower revenue than ProPhase Labs. Nexentis Technologies is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexentis Technologies	N/A	N/A	-$4M	-$114.15	N/A
ProPhase Labs	$5.06M	0.15	-$53.36M	-$3.13	N/A

Nexentis Technologies has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Nexentis Technologies' return on equity of -145.15% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexentis Technologies	N/A	-145.15%	-111.82%
ProPhase Labs	-825.01%	-482.05%	-88.90%

61.2% of Nexentis Technologies shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 6.5% of Nexentis Technologies shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Nexentis Technologies' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Nexentis Technologies	Neutral
ProPhase Labs	Neutral

Summary

Nexentis Technologies and ProPhase Labs tied by winning 5 of the 10 factors compared between the two stocks.

How does ProPhase Labs compare to Vaccinex?

ProPhase Labs (NASDAQ:PRPH) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Vaccinex had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 1 mentions for Vaccinex and 0 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Vaccinex	Neutral

Vaccinex has lower revenue, but higher earnings than ProPhase Labs. Vaccinex is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.15	-$53.36M	-$3.13	N/A
Vaccinex	$388K	6.63	-$20.25M	-$48.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ProPhase Labs has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

Vaccinex has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vaccinex's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Vaccinex	N/A	N/A	-383.58%

Summary

Vaccinex beats ProPhase Labs on 8 of the 13 factors compared between the two stocks.

How does ProPhase Labs compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GRI Bio has a beta of -1.2, suggesting that its share price is 220% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

GRI Bio has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. GRI Bio's return on equity of -199.52% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
ProPhase Labs	-825.01%	-482.05%	-88.90%

GRI Bio presently has a consensus price target of $32.00, suggesting a potential upside of 1,782.35%. Given GRI Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe GRI Bio is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GRI Bio had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for ProPhase Labs. GRI Bio's average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
GRI Bio	Neutral
ProPhase Labs	Neutral

GRI Bio has higher earnings, but lower revenue than ProPhase Labs. GRI Bio is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
ProPhase Labs	$5.06M	0.15	-$53.36M	-$3.13	N/A

Summary

GRI Bio beats ProPhase Labs on 8 of the 14 factors compared between the two stocks.

How does ProPhase Labs compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

CASI Pharmaceuticals has a net margin of -183.93% compared to ProPhase Labs' net margin of -825.01%. CASI Pharmaceuticals' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
ProPhase Labs	-825.01%	-482.05%	-88.90%

In the previous week, CASI Pharmaceuticals' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
ProPhase Labs	Neutral

CASI Pharmaceuticals has higher revenue and earnings than ProPhase Labs. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
ProPhase Labs	$5.06M	0.15	-$53.36M	-$3.13	N/A

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CASI Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

CASI Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe CASI Pharmaceuticals is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CASI Pharmaceuticals beats ProPhase Labs on 11 of the 14 factors compared between the two stocks.

How does ProPhase Labs compare to Moleculin Biotech?

ProPhase Labs (NASDAQ:PRPH) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Moleculin Biotech has a consensus target price of $22.00, suggesting a potential upside of 5,011.52%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Moleculin Biotech had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 1 mentions for Moleculin Biotech and 0 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.00 equaled Moleculin Biotech'saverage media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Moleculin Biotech	Neutral

Moleculin Biotech has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Moleculin Biotech's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Moleculin Biotech	N/A	N/A	-70.93%

ProPhase Labs has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market.

Moleculin Biotech has lower revenue, but higher earnings than ProPhase Labs. Moleculin Biotech is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.15	-$53.36M	-$3.13	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Moleculin Biotech beats ProPhase Labs on 10 of the 14 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPH vs. The Competition

Export

Metric	ProPhase Labs	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$777K	$11.81B	$7.01B	$12.98B
Dividend Yield	N/A	2.69%	2.58%	10.07%
P/E Ratio	-0.02	788.51	269.18	24.72
Price / Sales	0.15	747.68	589.72	98.19
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	0.02	10.28	11.34	6.42
Net Income	-$53.36M	$2.77B	$3.45B	$347.03M
7 Day Performance	N/A	0.86%	1.94%	0.71%
1 Month Performance	N/A	-1.58%	-0.56%	-0.87%
1 Year Performance	N/A	183.20%	75.50%	21.94%

ProPhase Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPH ProPhase Labs	N/A	$0.05 +42.3%	N/A	-98.4%	$777K	$5.06M	N/A	130	Upcoming Earnings Gap Up
NXTS Nexentis Technologies	0.8273 of 5 stars	$2.02 -2.4%	N/A	-96.9%	$2.93M	$210K	N/A	2	Gap Up
VCNX Vaccinex	N/A	$1.12 -2.6%	N/A	+41.4%	$2.91M	$388K	N/A	40	Gap Down
GRI GRI Bio	1.8471 of 5 stars	$1.59 +10.4%	$32.00 +1,912.6%	-95.2%	$2.81M	N/A	N/A	1	Upcoming Earnings
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPH) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProPhase Labs (PRPH) Competitors

PRPH vs. NXTS, VCNX, GRI, CASI, and MBRX

How does ProPhase Labs compare to Nexentis Technologies?

Summary

How does ProPhase Labs compare to Vaccinex?

Summary

How does ProPhase Labs compare to GRI Bio?

Summary

How does ProPhase Labs compare to CASI Pharmaceuticals?

Summary

How does ProPhase Labs compare to Moleculin Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProPhase Labs (PRPH) Competitors

PRPH vs. NXTS, VCNX, GRI, CASI, and MBRX

How does ProPhase Labs compare to Nexentis Technologies?

Which has more volatility and risk, NXTS or PRPH?

Do analysts recommend NXTS or PRPH?

Which has stronger earnings and valuation, NXTS or PRPH?

Is NXTS or PRPH more profitable?

Do institutionals and insiders have more ownership in NXTS or PRPH?

Does the media refer more to NXTS or PRPH?

Summary

How does ProPhase Labs compare to Vaccinex?

Do institutionals & insiders hold more shares of PRPH or VCNX?

Does the media refer more to PRPH or VCNX?

Which has stronger earnings & valuation, PRPH or VCNX?

Do analysts recommend PRPH or VCNX?

Which has more risk & volatility, PRPH or VCNX?

Is PRPH or VCNX more profitable?

Summary

How does ProPhase Labs compare to GRI Bio?

Do institutionals and insiders believe in GRI or PRPH?

Which has more volatility and risk, GRI or PRPH?

Is GRI or PRPH more profitable?

Do analysts rate GRI or PRPH?

Does the media favor GRI or PRPH?

Which has higher valuation and earnings, GRI or PRPH?

Summary

How does ProPhase Labs compare to CASI Pharmaceuticals?

Is CASI or PRPH more profitable?

Does the media favor CASI or PRPH?

Which has preferable earnings & valuation, CASI or PRPH?

Do institutionals & insiders have more ownership in CASI or PRPH?

Which has more risk & volatility, CASI or PRPH?

Do analysts prefer CASI or PRPH?

Summary

How does ProPhase Labs compare to Moleculin Biotech?

Do analysts rate PRPH or MBRX?

Does the media prefer PRPH or MBRX?

Is PRPH or MBRX more profitable?

Which has more volatility and risk, PRPH or MBRX?

Which has stronger earnings & valuation, PRPH or MBRX?

Do insiders & institutionals hold more shares of PRPH or MBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools